Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eyedrop lifts droopy eyelids after facial paralysis?

NCT ID NCT05945615

Symptom relief Sponsor: Milton S. Hershey Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an FDA-approved eyedrop (oxymetazoline 0.1%) in 36 adults with eyelid droop caused by facial nerve miswiring after paralysis. The goal was to see if the drop could temporarily raise the eyelid, improve vision, and reduce abnormal muscle spasms. Researchers measured changes in eyelid position, facial function, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oxymetazoline 0.1% ophthalmic solution (Upneeq)
What this could lead to
If it works, this could offer a simple eyedrop treatment to temporarily lift the eyelid and improve vision and appearance in people with eyelid droop after facial paralysis.
What could go wrong
This is a small, completed trial with only 36 participants. The medication is already FDA-approved for other causes of eyelid droop, but its effect on droop due to nerve miswiring may be limited or not last long.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

36 people

The number who actually took part.

Started

Jan 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Over 18 years of age 2. Primary diagnosis of nonflaccid facial paralysis (aberrant regeneration syndrome) and acquired blepharoptosis. Exclusion Criteria: 1. Patients under the age of 18 2. Patients on cardiac glycosides 3. Patients on MAO inhibitors 4. Patients with angle closure glaucoma 5. Patients who experience asymmetrical eye opening due to weakness (e.g. lagophthalmos).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acquired blepharoptosis due to periocular synkinesis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

facial paralysis familial congenital mirror movements Hyperkinesis jaw-winking syndrome ptosis Synkinesis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blepharoptosis Facial paralysis Hyperkinesis Synkinesis

Contacts and locations

Locations

  • M.S. Hershey Medical Center

    Hershey, Pennsylvania, 17033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.